CXCL9 and melanoma: Collectively, NPTyr-C9AP that locally coexpressed CXCL9 and αPD-L1 in melanoma was more potent in enhancing the intratumoral infiltration and activation of T cells than the systemic injection of anti-PD-L1 antibody, thereby inducing superior antimelanoma effects.